RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy

Song Dong1,2, Ai-Lin Guo1, Zhi-Hong Chen1, Zhen Wang1, Xu-Chao Zhang1, Ying Huang1, Zhi Xie1, Hong-Hong Yan1, Hua Cheng3, Yi-Long Wu1*

Abstract

Background: The ribonucleotide reductase M1 (RRM1) gene encodes the regulatory subunit of ribonucleotide reductase, the molecular target of gemcitabine. The overexpression of RRM1 mRNA in tumor tissues is reported to be associated with gemcitabine resistance. Thus, single nucleotide polymorphisms (SNPs) of the RRM1 gene are potential biomarkers of the response to gemcitabine chemotherapy. We investigated whether RRM1 expression in peripheral blood mononuclear cells (PBMCs) or SNPs were associated with clinical outcome after gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.

Methods: PBMC samples were obtained from 62 stage IIIB and IV patients treated with gemcitabine-based chemotherapy. RRM1 mRNA expression levels were assessed by real-time PCR. Three RRM1 SNPs, -37C→A, 2455A→G and 2464G→A, were assessed by direct sequencing.

Results: RRM1 expression was detectable in 57 PBMC samples, and SNPs were sequenced in 56 samples. The overall response rate to gemcitabine was 18%; there was no significant association between RRM1 mRNA expression and response rate (P = 0.560). The median progression-free survival (PFS) was 23.3 weeks in the lower expression group and 26.9 weeks in the higher expression group (P = 0.659). For the -37C→A polymorphism, the median PFS was 30.7 weeks in the C(-)37A group, 24.7 weeks in the A(-)37A group, and 23.3 weeks in the C(-)37C group (P = 0.043). No significant difference in PFS was observed for the SNP 2455A→G or 2464G→A.

Conclusions: The RRM1 polymorphism -37C→A correlated with PFS in NSCLC patients treated with gemcitabine-based chemotherapy. No significant correlation was found between PBMC RRM1 mRNA expression and the efficacy of gemcitabine.

Background

Lung cancer is a leading cause of cancer deaths in both China and the USA [1,2]. More than 75% of lung cancers are non-small cell lung cancer (NSCLC) [3]. Most patients have advanced NSCLC when diagnosed, and chemotherapy is one of the major treatment options in these patients. A meta-analysis showed the importance of gemcitabine in the treatment of advanced NSCLC; median survival with gemcitabine-based chemotherapy was 9 months, versus 8.2 months with non-gemcitabine combinations [4]. However, resistance to gemcitabine or relapse soon after treatment has limited the efficacy of this drug.

The molecular target of gemcitabine is ribonucleotide reductase [5]. This enzyme catalyzes the rate-limiting step in deoxyribonucleotide formation and is the only known enzyme that converts ribonucleotides to deoxyribonucleotides, which are required for DNA polymerization and repair [6]. The RRM1 gene encodes the regulatory subunit of ribonucleotide reductase; diphosphorylated gemcitabine (dFdDDP) indirectly inhibits DNA synthesis through the inhibition of RRM1 [7].

In patients with advanced NSCLC, RRM1 mRNA expression levels are related to the efficacy of gemcitabine therapy. Retrospective studies of stage IV NSCLC...
patients treated with gemcitabine-based chemotherapy have shown that patients with low tumor RRM1 mRNA levels lived longer than patients with higher expression levels [8-11]. Furthermore, the efficacy of gemcitabine plus docetaxel can be improved when specifically administered according to the tumor mRNA expression of BRCA1, RRM1, and RRM2. An association between RRM1 overexpression and resistance to gemcitabine has been observed in the laboratory [12,13]. Thus, customized chemotherapy based on tumor RRM1 expression is a reasonable strategy for advanced NSCLC patients. Nevertheless, it is difficult to ordinarily use tumor RRM1 mRNA levels as a predictor to determine optimal chemotherapy regimens in clinical practice. As some advanced NSCLC patients are diagnosed only by cytopathology or needle biopsy with a small amount of tumor tissue, insufficient material may be available for gene expression analysis. More convenient and precise biomarkers are needed.

SNPs represent natural genetic variability at a high density in the human genome and have been confirmed as predictive markers of some treatment responses [14]. An advantage of SNPs as predictive markers is that genomic DNA can be analyzed from samples of PBMCs, even when tumor mRNA is not available from patients with advanced NSCLC. An adenine→cytosine substitution in the 5’ non-coding region of RRM1, located 37 nucleotides upstream of the start codon, has been associated with higher RRM1 expression levels[15]. Furthermore, -37C→A alone and the allelotypes C(-)37A-C(-) 524T were related to chemotherapy outcome in clinical trials[16,17].

In this study, we examined RRM1 mRNA expression in PBMCs by real-time reverse transcription PCR and analyzed the SNPs by direct sequencing. The possibility of using PBMC RRM1 expression or SNPs as efficacy predictors in NSCLC patients treated with gemcitabine was tested.

Results

Patient characteristics and efficacy of treatment

Between March 2006 and February 2007, 62 eligible patients were enrolled. The patients’ ages ranged from 35 to 70 years (median, 61); 21 were women. Among the 62 patients, 59 were naive to any previous anticancer treatment, two had suffered recurrences after surgical resection, and one had received whole-brain radiotherapy. All patients received at least one cycle of chemotherapy. Baseline characteristics of the 62 patients are shown in Table 1. No patient had CR, 11 patients had PR, 44 patients had SD, and 7 patients had PD. The median progression-free survival (PFS) was 22.8 weeks.

Table 1 Baseline characteristics of the 62 patients

| Characteristic          | n (%)            |
|-------------------------|------------------|
| Gender                  |                  |
| Male                    | 40 (64.5)        |
| Female                  | 22 (35.5)        |
| Age                     |                  |
| ≤ 65 years              | 50 (80.6)        |
| >65 years               | 12 (19.4)        |
| WHO PS                  |                  |
| 0                       | 11 (17.7)        |
| 1                       | 51 (82.3)        |
| Histology               |                  |
| Squamous cell carcinoma | 11 (17.7)        |
| Adenocarcinoma          | 46 (74.2)        |
| Large cell carcinoma    | 3 (4.8)          |
| Other NSCLC             | 2 (3.3)          |
| Stage                   |                  |
| IIIA                    | 2 (3.3)          |
| IIIB                    | 10 (16.1)        |
| IV                      | 50 (80.6)        |
| Weight loss ≥5%         |                  |
| Yes                     | 13 (21.0)        |
| No                      | 47 (75.8)        |
| Unknown                 | 2 (3.2)          |

RRM1 expression and treatment efficacy

Amplification of RRM1 was successful in 57 samples, and we failed to extract RNA from five blood samples. There was considerable variation in the expression level, with relative expression values ranging from 1.81 × 10^-6 to 7.78 × 10^-2 (median, 1.54 × 10^-4; mean, 6.48 × 10^-3). Patients were divided into two groups, those with expression equal to or higher than the median and those with expression below the median. No differences in clinical characteristics, including age, gender, histological type, and stage, were observed between the groups, and there was no significant association between RRM1 expression and response (P = 0.560). Table 2 shows the baseline characteristics and response according to RRM1 expression in PBMCs.

We used a log-rank test to analyze the level of significance between PFS and RRM1 expression. The median PFS was 23.3 weeks (95% CI, 15.3-31.3) in the lower-expression group and 23.9 weeks (95% CI, 22.8-31.0) in the higher-expression group, with no significant association between RRM1 mRNA expression and PFS (P = 0.659; Fig. 1).

SNP genotype and efficacy of gemcitabine

Blood samples from 56 patients were available for the analysis of RRM1 SNPs. An analysis of sequence chromatograms revealed RRM1 polymorphisms (Fig. 2). The allele
frequencies for -37C→A were 0.196 (11/56) for A(-)37A, 0.428 (24/56) for C(-)37C, and 0.376 (21/56) for C(-)37A; for 2455A→G, 0.482 (27/56) for A2455A, 0.214 (12/56) for G2455G, and 0.304 (17/56) for A2455G; and for 2464G→A, 0.554 (31/56) for A2464A, 0.142 (8/56) for G2464G, and 0.304 (17/56) for G2464A. Kendall’s tau correlation was used to test the relationship between genotype and chemotherapy response, but no significant association was found (-37C→A, \(P = 0.514\); 2455A→G, \(P = 0.849\); 2464G→A, \(P = 0.191\)). For the polymorphism -37C→A, the median PFS was 30.7 weeks (95% CI, 24.5-36.9) for the C(-)37A genotype, 24.7 weeks (95% CI, 6.8-42.6) for A(-)37A, and 23.3 weeks for C(-)37C (95% CI, 20.8-25.8; \(P = 0.043\)). No genotype of 2455A→G or 2464G→A showed a significant correlation with sensitivity to gemcitabine (Table 3; Fig. 3A-C).

### RRM1 genotype and mRNA expression

Paired DNA/mRNA was successfully extracted from 53 blood samples. The mRNA expression levels were compared according to SNP genotype, and no significant difference was found (-37C→A, \(P = 0.693\); 2455A→G, \(P = 0.081\); 2464G→A, \(P = 0.650\)).

### Table 2 Baseline characteristics by RRM1 expression

| Characteristic | RRM1 mRNA Expression | \(P\) value |
|---------------|-----------------------|-------------|
| Age, years    |                       |             |
| \(\geq 62\)   | Low: 14, High: 11     |             |
| <62           | Low: 14, High: 18     | 0.592       |
| Gender        |                       |             |
| Male          | Low: 20, High: 19     |             |
| Female        | Low: 8, High: 10      | 0.501       |
| WHO PS        |                       |             |
| 0             | Low: 2, High: 9       |             |
| 1             | Low: 26, High: 20     | 0.062       |
| Smoking       |                       |             |
| Yes           | Low: 15, High: 13     |             |
| No            | Low: 13, High: 16     | 0.207       |
| Weight loss ≥ 5% |                   |             |
| Yes           | Low: 4, High: 8       |             |
| No            | Low: 24, High: 19     |             |
| Unknown\(^2\) | Low: 0, High: 2       | 0.348       |
| Histology     |                       |             |
| Adenocarcinoma| Low: 19, High: 22     |             |
| Squamous cell carcinoma | Low: 6, High: 6 |             |
| Others\(^2\)  | Low: 3, High: 1       | 0.833       |
| Stage         |                       |             |
| III           | Low: 3, High: 7       |             |
| IV            | Low: 25, High: 22     | 0.257       |

\(^1\) mRNA from 57 samples was available for the analysis of RRM1 expression. \(^2\) These groups were excluded from the statistical analysis.

### RRM1 genotype and toxicity

All patients who received at least one cycle of chemotherapy were included in the toxicity analysis. Hematological toxicity grade ≥ 2 was observed in 22 patients, and grade 3/4 was seen in 12 patients. Hepatotoxicity grade ≥ 2 was observed in two patients; vomiting grade ≥ 2, in two patients; and rash grade ≥ 2, in one patient. Hematological toxicity grade 3/4 was observed in 50% of patients (9/18) harboring A2455G and in 7.7% of patients (3/39) harboring homozygous G2455G or A2455A (\(r = 0.482, P < 0.001\)). No other significant difference was observed according to SNP genotype.

### Discussion

The use of gene expression as a predictive marker for the efficacy of chemotherapy is an important area of translational research. We wanted to know whether RRM1 mRNA expression in PBMCs could serve as a substitute for predicting the efficacy of gemcitabine-based chemotherapy. To test this, venous blood was collected before chemotherapy and gene expression was analyzed, but no association was found between RRM1 mRNA expression in PBMCs and the efficacy of gemcitabine treatment. We also analyzed RRM1 expression in lung tumors and adjacent normal lung tissue from 17 patients who had undergone surgery and found no significant association between RRM1 expression in lung tumor cells and in normal lung tissue (data no shown). In this study, all of the 62 patients were diagnosed with advanced NSCLC, so tumor tissue or normal lung tissue was not available for the analysis of any correlation between RRM1 expression in PBMCs and in normal tissue.

Ribonucleotide reductase is involved in the proliferation and metabolism of cells; the proliferative characteristics of cancer cells are different from those of pulmonary epithelial cells and other cells in normal lung tissue. On the other hand, the PBMCs mainly contain lymphocytes and monocytes which are critical in the immune system with different proliferative activity. So we speculated that the simple comparison of mRNA expression between PBMCs and cancer cells is unavailable.

Genetic polymorphisms may affect protein structure, function, stability, or folding. The most common form of polymorphism in the human genome is a SNP, and some SNPs have been shown to correlate with drug sensitivity and toxicity. In a previous study, we found that the intron 1 (CA) repeat genetic polymorphisms of the epidermal growth factor receptor (EGFR) gene were correlated with EGFR protein expression and clinical response in NSCLC patients treated with EGFR tyrosine kinase inhibitor[18]. To find markers that could predict gemcitabine sensitivity, we analyzed the

### Table 3 Baseline characteristics by RRM1 expression

| Characteristic | RRM1 mRNA Expression | \(P\) value |
|---------------|-----------------------|-------------|
| Age, years    |                       |             |
| \(\geq 62\)   | Low: 14, High: 11     |             |
| <62           | Low: 14, High: 18     | 0.592       |
| Gender        |                       |             |
| Male          | Low: 20, High: 19     |             |
| Female        | Low: 8, High: 10      | 0.501       |
| WHO PS        |                       |             |
| 0             | Low: 2, High: 9       |             |
| 1             | Low: 26, High: 20     | 0.062       |
| Smoking       |                       |             |
| Yes           | Low: 15, High: 13     |             |
| No            | Low: 13, High: 16     | 0.207       |
| Weight loss ≥ 5% |                   |             |
| Yes           | Low: 4, High: 8       |             |
| No            | Low: 24, High: 19     |             |
| Unknown\(^2\) | Low: 0, High: 2       | 0.348       |
| Histology     |                       |             |
| Adenocarcinoma| Low: 19, High: 22     |             |
| Squamous cell carcinoma | Low: 6, High: 6 |             |
| Others\(^2\)  | Low: 3, High: 1       | 0.833       |
| Stage         |                       |             |
| III           | Low: 3, High: 7       |             |
| IV            | Low: 25, High: 22     | 0.257       |

\(^1\) mRNA from 57 samples was available for the analysis of RRM1 expression. \(^2\) These groups were excluded from the statistical analysis.
SNPs of RRM1, the target of gemcitabine. Based on previous reports, we selected the polymorphism sites -37C→A, 2455A→G, and 2464G→A as target SNPs. The RRM1 polymorphism C(-)37A affects promoter activity in vitro [19] but the use of a single genetic polymorphism, -37C→A, as predictor was uncertain [17,20]. Gemcitabine sensitivity has been associated with RRM1 A2464A in vitro [21], but no similar result has been observed in breast cancer patients [22]. As mentioned above, the values of these SNPs were different in previous studies and we considered it necessary to analyze these SNP sites.

The -37C→A polymorphism is located in the promoter region, upstream of the transcriptional start point. Given that promoter activity is one of the factors controlling RRM1 expression, we expect that polymorphism at -37C→A affects promoter activity. We noticed that 27.3% of the patients (6/22) showing a partial response harbored C(-)37A, but only 8.8% of the patients homozygous at -37C→A had a partial response; This SNP had no significant association with response rates (P = 0.353). Limited by the period of study, only 62 patients were enrolled, we expected that relationship between SNPs and response could be understood if there were enough cases, but the PFS of patients with A(-)37C was significantly different from that of patients with the other genotypes (P = 0.043). Heterozygous A2455G was present in 50% of patients (9/18) with grade 3/4 hematological toxicity (r = 0.482, P < 0.001); thus, we suggest that patients harboring A2455G may be more susceptible to gemcitabine, although no significant association was observed between A2455G and chemotherapy outcome, maybe this is due to the limitation of sample size. The SNPs 2455A→G and 2464G→A are located at the end of the RRM1 cDNA; as both are synonymous SNPs, the amino acid would not be different among the genotypes. However, a previous report showed that a synonymous SNP in RRM1 gene was correlated with gene expression level [23]. We hypothesize that the 2455A→G polymorphism may affect the efficiency of RRM1 mRNA transcription, resulting in different mRNA expression levels; this needs further investigation.

Based on our results, we cannot determine whether the RRM1 mRNA expression level in PBMCs is useful in predicting the efficacy of gemcitabine-based chemotherapy. However, regarding SNPs, patients harboring the C(-)37A genotype had a longer PFS with gemcitabine-based chemotherapy than patients with the other SNPs. Studies with larger populations are necessary to validate the possible value of this RRM1 SNP in gemcitabine-based chemotherapy.
Conclusions
The RRM1 polymorphism -37C→A correlated with PFS in NSCLC patients treated with gemcitabine-based chemotherapy. No significant correlation was found between PBMC RRM1 mRNA expression and the efficacy of gemcitabine.

Patients and Methods
Patients
Advanced NSCLC patients treated at Guangdong General Hospital were enrolled. Eligibility criteria included a histological or cytological diagnosis of stage III B and IV NSCLC, WHO performance status (PS) of 0-1, age >18 years, no prior chemotherapy or thoracic radiation, and adequate bone marrow, liver, and kidney function. All patients were treated with gemcitabine/carboplatin regimen as a first line chemotherapy, patients received gemcitabine 1000 mg/m² on days 1 and 8, and carboplatin, AUC = 5, on day 1, every 21 days for a maximum of four cycles. Using the Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines, response was assessed with a computed tomography (CT) scan after two cycles of chemotherapy and was confirmed after four cycles. Patients have follow-up visit every 3 months with CT scan for 1 year. The study was approved by the Ethics Committee of the Guangdong General Hospital. Written informed consent was obtained from all patients.

Figure 2 Sequence chromatograms for polymorphisms are shown. The arrows indicate the polymorphic positions. A: A2455A and A2464A (antisense). B: A2455G and G2464A (antisense). C: A(-)37A (antisense). D: C(-)37C (sense). E: A(-)37C (antisense).
Before the first round of chemotherapy, a venous blood sample (4 mL) from each patient was collected in tubes containing EDTA (50 mmol/L). Total RNA was extracted from PBMCs using Trizol reagent (Invitrogen, Carlsbad, CA). Genomic DNA was extracted by the citrate sodium method, according to the protocol in the manual for Trizol LS reagent [http://tools.invitrogen.com/content/sfs/manuals/10296010.pdf].

**RRM1 expression analysis**

The cDNA was generated from RNA with a SuperScript™ III First-Strand Synthesis System (Invitrogen). Using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA), real-time quantitative PCR for RRM1 and the housekeeping gene β-actin was conducted, with 5 ng of cDNA per reaction. The gene copy number of β-actin was used as an internal control. For standard curve determination, plasmids containing the same target sequences were used as standards; relative gene expression quantification was calculated according to the copy number of RRM1. The standardized copy number was determined by dividing the target copy number by the calibrator copy number.

**RRM1 SNP genotyping**

To check for SNPs in RRM1 (-37C→A, 2455A→G, 2464G→A), PCR amplification of genomic DNA was performed, followed by direct sequencing. Primer pairs were designed based on the published RRM1 sequence (GenBank accession number AF107045): -37C→A primers, F-5′-TTAACCGCCTTTCCCTCGG-3′ and R-5′-GGGATTTGGATTTGCCG-3′; 2455A→G and

### Table 3 Response and PFS by RRM1 SNPs

| RRM1 SNPs | Response¹ (n) | P value² | PFS(weeks) | P value³ |
|-----------|---------------|----------|------------|----------|
|           | PR | SD | PD |         |         |
| A(-)37A   | 1  | 7  | 2  | 24.7     |          |
| C(-)37C   | 2  | 20 | 2  | 23.3     |          |
| A(-)37C   | 6  | 14 | 2  | 0.514    | 30.7     | 0.043    |
| A2455A    | 5  | 22 | 2  | 26.9     |          |
| G2455G    | 2  | 6  | 3  | 22.0     |          |
| A2455G    | 2  | 13 | 1  | 0.849    | 30.7     | 0.327    |
| G2464G    | 0  | 7  | 1  | 23.9     |          |
| A2464A    | 6  | 20 | 5  | 24.7     |          |
| G2464A    | 3  | 13 | 1  | 0.191    | 27.4     | 0.973    |

1 Genomic DNA from 56 patients was available for the analysis of RRM1 SNPs and response.
2 Kendall’s tau correlation
3 Kaplan-Meier survival estimates.

Abbreviations: PR, Partial response; SD, Stable disease; PD, Progressive disease; PFS, Progression-free survival.

**Figure 3 Kaplan-Meier survival estimates based on RRM1 SNPs**

(A-C) for patients with NSCLC.
carried out the gene sequencing. ZW and XZ participated in the design of the study. YW and AG participated in its design and coordination and helped to draft the manuscript. HC and HY participated in the collection of samples and follow-up. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 19 January 2010 Accepted: 13 March 2010 Published: 13 March 2010

References
1. Chen WQ: Estimation of cancer incidence and mortality in China in 2004-2005. Zhonghua zhi zhi li xue za zhong [Chinese journal of oncology] 2009, 31:664-668.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA: a cancer journal for clinicians 2009, 59:225-249.
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899-909.
4. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, van Saene-Hurks L, Thatcher N, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung cancer (Amsterdam, Netherlands) 2005, 47:69-80.
5. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bellger P, Novello S, Cooc J, Cino L, Sanchez JJ, Taron M, et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3553.
6. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer research 2004, 64:3761-3766.
7. Pereira S, Fernandes PA, Ramos MJ: Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. Journal of computational chemistry 2004, 25:1286-1296.
8. Rosell R, Danenberg KD, Alboreal V, Bellger P, Sanchez JJ, Camps C, Provenco M, Ida D, Taron M, Diz P, Artal A: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
9. Crippa P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambie A, Veghelli G, Saviozzi S, Calogero R, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
10. Boukouvinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsiopoulos S, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Stathopoulos E, et al: Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small cell lung cancer patients. PloS one 2008, 3:e3695.
11. Bellger P, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
12. Goan YG, Zhou B, Hu E, Mi S, Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer research 1999, 59:4204-4207.
13. Gautam A, Li ZR, Bellger P: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003, 22:2135-2142.
14. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung cancer (Amsterdam, Netherlands) 2004, 44:311-316.
15. Bellger P, Sharma S, Gautam A, Smith P, Zheng Z, Hofmann J, Simonet G: Tumor genotype, RRM1 expression and outcome of patients with lung cancer. Eur J Cancer 2002, 38:862-83.
l lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14:3083-3088.

17. Sarries C, Alberola V, De Las Peñas A, Camps C, Massuti B, Garcia-Gomez R, Insa A, Sanchez-Ronco M, Taron M, Rosell R. Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients (gr). J Clin Oncol 2004, 14(suppl):7031.

18. Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. The epidermal growth factor receptor intron1 (CA)n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol 2007, 570:175-181.

19. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer (Amsterdam, Netherlands) 2005, 47:183-192.

20. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.

21. Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006, 16:429-438.

22. Rha SY, Jeung HC, Choi YH, Yang WH, Yoo JH, Kim BS, Roh JK, Chung HC. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 2007, 12:622-630.

23. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000, 97:3473-3478.

doi:10.1186/1756-8722-3-10
Cite this article as: Dong et al. RRM1 single nucleotide polymorphism -37C>A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. Journal of Hematology & Oncology. 2010 3:10.